DeepClassPathway: Molecular pathway aware classification using explainable deep learning.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
11 2022
Historique:
received: 07 07 2022
accepted: 25 08 2022
pubmed: 4 10 2022
medline: 22 11 2022
entrez: 3 10 2022
Statut: ppublish

Résumé

HPV-associated head and neck cancer is correlated with favorable prognosis; however, its underlying biology is not fully understood. We propose an explainable convolutional neural network (CNN) classifier, DeepClassPathway, that predicts HPV-status and allows patient-specific identification of molecular pathways driving classifier decisions. The CNN was trained to classify HPV-status on transcriptome data from 264 (13% HPV-positive) and tested on 85 (25% HPV-positive) head and neck squamous carcinoma patients after transformation into 2D-treemaps representing molecular pathways. Grad-CAM saliency was used to quantify pathways contribution to individual CNN decisions. Model stability was assessed by shuffling pathways within 2D-images. The classification performance of the CNN-ensembles achieved ROC-AUC/PR-AUC of 0.96/0.90 for all treemap variants. Quantification of the averaged pathway saliency heatmaps consistently identified KRAS, spermatogenesis, bile acid metabolism, and inflammation signaling pathways as the four most informative for classifying HPV-positive patients and MYC targets, epithelial-mesenchymal transition, and protein secretion pathways for HPV-negative patients. We have developed and applied an explainable CNN classification approach to transcriptome data from an oncology cohort with typical sample size that allows classification while accounting for the importance of molecular pathways in individual-level decisions.

Identifiants

pubmed: 36191385
pii: S0959-8049(22)00533-0
doi: 10.1016/j.ejca.2022.08.033
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-49

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Elia Lombardo (E)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.

Julia Hess (J)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Christopher Kurz (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.

Marco Riboldi (M)

Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Garching, 85748, Germany.

Sebastian Marschner (S)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.

Philipp Baumeister (P)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, 81377, Germany.

Kirsten Lauber (K)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Ulrike Pflugradt (U)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Axel Walch (A)

Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Garching, 85748, Germany; Research Unit Analytical Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Martin Canis (M)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, 81377, Germany.

Frederick Klauschen (F)

Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, 81377, Germany.

Horst Zitzelsberger (H)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Claus Belka (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, 81377, Germany.

Guillaume Landry (G)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.

Kristian Unger (K)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany. Electronic address: unger@helmholtz-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH